Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C

Hospital Clinic of Barcelona

Status and phase

Completed

Phase 4

Conditions

Liver Fibrosis

Chronic Hepatitis C

Treatments

Drug: Losartan

Study type

Interventional

Funder types

Other

Identifiers

NCT00298714

Protocol number: 02-0491

ARAHEPC

Details and patient eligibility

About

There is evidence on the beneficial effects of the administration of angiotensin II type 1 (AT1) receptors antagonists on liver fibrosis in hepatic stellate cells, experimental models of liver fibrosis in rodents and limited information in chronic hepatitis C with mild fibrosis.

The purpose of this study is to investigate the effect of long-term administration of oral Losartan, an AT1 receptor antagonist, on liver fibrogenesis in patients with chronic hepatitis C and fibrosis F2-F3 (METAVIR score).

Sex

All

Ages

35 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

age between 35 and 65 years
chronic hepatitis C with intermediate fibrosis (F2-F3 in Metavir score).
non-responder or contraindication to antiviral therapy.

Exclusion criteria

any other cause of liver disease
HIV positive
alcohol consumption
arterial hypertension
creatinine > 1.5mg/dL
treatment with AT1 receptor antagonists or angiotensin converting enzyme inhibitors in the past 12 months.
antiviral therapy in the past 12 months
contraindications to oral losartan